| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/30/2002 | US20020065210 DcR3 polypeptide, a TNFR homolog |
| 05/30/2002 | US20020065046 Apparatuses, methods, and computer programs for showing information on a vehicle having multiple displays |
| 05/30/2002 | US20020064872 Polypeptide for use in the detection and prevention of tumors; antitumor agents; anticarcinogenic agents |
| 05/30/2002 | US20020064869 Polypeptide for use in treatment of lymphadenopathy, autoimmune disease and graft versus host disease; antitumor agents |
| 05/30/2002 | US20020064862 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity |
| 05/30/2002 | US20020064858 Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064855 Nucleotide sequences for use in the treatment of leukemia |
| 05/30/2002 | US20020064853 Nucleotide sequences coding enzymatic polypeptide for use in treatment of cancer, nervous system, cardiovascular and inflammatory disorders, restenosis and arteriosclerosis |
| 05/30/2002 | US20020064851 Peptide for use in development of human diagnostics and therapeutics; for use in deection and treatment of cancer, inflammation, immune disorders and development defects |
| 05/30/2002 | US20020064848 Novel histidinol dehydrogenase |
| 05/30/2002 | US20020064844 Nucleotide sequences coding enzymatic polypeptide for use in the diagnostic tool in detection, prevention and treatment of nervous system, reproductive and vascular systems disorders |
| 05/30/2002 | US20020064835 Generating muscle protein; obtain sample, incubate under reducing environment, recover muscle protein |
| 05/30/2002 | US20020064832 Method of treating fibroproliferative disorders |
| 05/30/2002 | US20020064831 Nucleotide sequences coding polypeptides associated capillary morphogenesis; for use in controlling neovascularization; antitumor agents |
| 05/30/2002 | US20020064828 Method of controlling the binding of calmyrin to presenilin |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064823 Nucleotide sequences which code binding protein for use in human therapeutics and gene therapy |
| 05/30/2002 | US20020064822 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 05/30/2002 | US20020064820 Apo-A-I regulation of T-cell signaling |
| 05/30/2002 | US20020064818 Nucleotide sequences coding preferential polypeptide; for use in diagnosis and treatment of cancer, nervous system, inflammatory and immunological disorders |
| 05/30/2002 | US20020064815 Ovarian tumor antigen and methods of use therefor |
| 05/30/2002 | US20020064813 Nucleotide sequences for use in the treatment of infections, pain; cancers; diabetes, eating, psychological, urogenital and neurological disorders; hypotension; hypertension; osteoporosis; angina pectoris; stroke; ulcers; allergies |
| 05/30/2002 | US20020064811 Dna encoding the human synapsin iii gene and uses thereof |
| 05/30/2002 | US20020064786 Cancer diagnosis and therapy based on mutations in TGF-beta receptors |
| 05/30/2002 | US20020064785 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| 05/30/2002 | US20020064783 Inhibition of bone tumor formation using antisense cDNA therapy |
| 05/30/2002 | US20020064770 Detecting preferential receptor associating protein; obtain library, incubate with receptor, detect bound receptor complex, isolate receptor associating protein |
| 05/30/2002 | US20020064570 Treating ulcerative colitis, reducing side effects of cancer treatments, improving the bowel movement of a patient who has undergone intestinal ablation or has an artificial anus |
| 05/30/2002 | US20020064568 Product and method for treating joint disorders in vertebrates |
| 05/30/2002 | US20020064549 Insulin supplemented infant formula |
| 05/30/2002 | US20020064539 Cosmetic or dermatological composition contacting at least one natural or recombinant spider silk or an analog |
| 05/30/2002 | US20020064538 Using a compound that inhibits or induces expression of tropoelastin mRNA or protein in keratinocytes; prevents photoaging |
| 05/30/2002 | US20020064536 Immobilizing a mammal by administering the toxin with a polysaccharide stabilizer, nonimmunogenic; use after surgery such as hip displasia or to recover from leg injuries in domestic animals |
| 05/30/2002 | US20020064535 Such as human granulocytic ehrlichiosis; polypeptides of antigenic portion(s) of an Ehrlichia antigen and DNA sequences encoding them; vaccines; detection kits |
| 05/30/2002 | US20020064530 Variants of phleum pratense allergenic proteins |
| 05/30/2002 | US20020064527 Administering agents that hinder CD30/CD30L (CD30L=ligand of CD30) binding; animal model of arthritis for drug screening |
| 05/30/2002 | US20020064523 SynMuv genes act as negative regulators of nematode Caenorhabditis elegans signalling pathway; tumor suppressor proteins; nucleic acids, proteins, antibodies; diagnosis of proliferative disorders |
| 05/30/2002 | US20020064518 Fermented product produced by adding a manganese-containing natural material (e.g. tea) and fermenting with bacteria having catalase activity |
| 05/30/2002 | US20020064516 Pharmaceutical compositions comprising TGF-beta |
| 05/30/2002 | US20020064515 Administering synergistic mixtures of immunostimulatory CpG oligonucleotides with unmethylated cytosine and guanine in given sequence, and immunopotentiating cytokines; treating tumors; contraceptive |
| 05/30/2002 | US20020064501 Determining peptide's therapeutic effect by administering to subject prone to showing signs of diabetes; determining development of diabetes |
| 05/30/2002 | US20020063763 Apparatus and method for removing air bubbles from an ink jet printhead |
| 05/30/2002 | US20020062835 Methods of modulating hair growth |
| 05/30/2002 | CA2434760A1 Differentiated cells suitable for human therapy |
| 05/30/2002 | CA2429856A1 Adapter protein and gene encoding it |
| 05/30/2002 | CA2429712A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 05/30/2002 | CA2429699A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/30/2002 | CA2429649A1 Drugs and foods improving the quality of life and process for producing the same |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429576A1 Fungal gene cluster associated with pathogenesis |
| 05/30/2002 | CA2427334A1 Methods and compositions for the treatment of diseases of the eye |
| 05/30/2002 | CA2426939A1 Cystoskeleton-associated proteins |
| 05/30/2002 | CA2426929A1 Treatment of osteoporosis |
| 05/30/2002 | CA2398924A1 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof |
| 05/30/2002 | CA2363951A1 Modulating ramp activity |
| 05/30/2002 | CA2327208A1 Methods of increasing distribution of therapeutic agents |
| 05/29/2002 | EP1209931A1 A method for setting up a connection of a mobile station in a cellular telecommunication system |
| 05/29/2002 | EP1209240A1 Novel compound f-15078 |
| 05/29/2002 | EP1209231A1 Meg-1 protein |
| 05/29/2002 | EP1209230A1 MODIFIED cDNA OF RAT bcl-x GENE AND MODIFIED PROTEIN |
| 05/29/2002 | EP1209226A2 Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) |
| 05/29/2002 | EP1209147A1 Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient |
| 05/29/2002 | EP1208849A1 Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing process |
| 05/29/2002 | EP1208848A1 Stable lactase compositions |
| 05/29/2002 | EP1208847A2 Pharmaceutical compositions for treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-O(2-hydroxyethyl)-rapamycin |
| 05/29/2002 | EP1208846A2 Non-aqueous polar aprotic peptide formulations |
| 05/29/2002 | EP1208842A2 Regulation of the immune system |
| 05/29/2002 | EP1208381A2 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 05/29/2002 | EP1208380A2 Cancer associated antigens and uses therefor |
| 05/29/2002 | EP1208377A1 Melanocortin metallopeptide constructs, combinatorial libraries and applications |
| 05/29/2002 | EP1208242A1 Antisense modulation of pepck-mitochondrial expression |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208228A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 05/29/2002 | EP1208217A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 05/29/2002 | EP1208202A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208199A2 DNA CODING FOR $g(b)-TUBULIN AND USE THEREOF |
| 05/29/2002 | EP1208198A2 Egfh2 genes and gene products |
| 05/29/2002 | EP1208197A1 Iren protein, its preparation and use |
| 05/29/2002 | EP1208196A1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 05/29/2002 | EP1208195A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/29/2002 | EP1208191A1 13 human colon and colon cancer associated proteins |
| 05/29/2002 | EP1208133A1 Copolymers for the transfer of nucleic acids to the cell |
| 05/29/2002 | EP1208116A2 Somatostatin analogs, radiolabelled derivatives thereof and their use |
| 05/29/2002 | EP1208115A2 Feline interleukin-12 as an immune stimulant |
| 05/29/2002 | EP1208114A2 Induction of programmed cell death by n5 gene |
| 05/29/2002 | EP1208112A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene |
| 05/29/2002 | EP1208110A1 Antisense modulation of focal adhesion kinase expression |
| 05/29/2002 | EP1208103A2 Reverse-turn mimetics and methods relating thereto |
| 05/29/2002 | EP1207906A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| 05/29/2002 | EP1207905A1 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| 05/29/2002 | EP1207902A2 USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES |
| 05/29/2002 | EP1207901A2 Use of natriuretic peptides as antibiotically effective substances for treating bacterial infections |
| 05/29/2002 | EP1207900A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 05/29/2002 | EP1207899A2 Treatment of allergic rhinitis |
| 05/29/2002 | EP1207898A2 Treatment of conjunctivitis |
| 05/29/2002 | EP1207897A2 Pharmaceutical compositions containing tripeptides |
| 05/29/2002 | EP1207896A1 Methods and compositions for reducing serum phosphate levels |